-
1
-
-
84924946876
-
-
American Cancer Society. Prostate Cancer. 2013
-
American Cancer Society. Prostate Cancer. 2013.
-
-
-
-
2
-
-
33750726077
-
Clinical features of metastatic bone disease and risk of skeletal morbidity
-
PID: 1706270
-
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s–9s.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6243-6249
-
-
Coleman, R.E.1
-
3
-
-
77953229266
-
-
Nørgaard M, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 184(1):162-167
-
Nørgaard M, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 184(1):162-167.
-
-
-
-
4
-
-
33645834966
-
Metastatic patterns in adenocarcinoma
-
PID: 1651882
-
Hess KR et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33.
-
(2006)
Cancer
, vol.106
, Issue.7
, pp. 1624-1633
-
-
Hess, K.R.1
-
5
-
-
79952360832
-
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
-
COI: 1:CAS:528:DC%2BC3MXjsVyrt70%3D, PID: 21353695, Osteoclast inhibitors represent an important class of pharmaceutical in this patient population. This randomized study was seminal in establishing the superiority of Denosumab to the only bisphosphonate that has consistently demonstrated benefit, Zoledronic acid
-
Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22. Osteoclast inhibitors represent an important class of pharmaceutical in this patient population. This randomized study was seminal in establishing the superiority of Denosumab to the only bisphosphonate that has consistently demonstrated benefit, Zoledronic acid.
-
(2011)
Lancet
, vol.377
, Issue.9768
, pp. 813-822
-
-
Fizazi, K.1
-
6
-
-
43949146650
-
The cost of treating skeletal-related events in patients with prostate cancer
-
Lage MJ et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manage Care. 2008;14(5):317–22.
-
(2008)
Am J Manage Care
, vol.14
, Issue.5
, pp. 317-322
-
-
Lage, M.J.1
-
7
-
-
84903476624
-
Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases
-
PID: 2450341
-
Zustovich F, Fabiani F. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. Crit Rev Oncol Hematol. 2014;91(2):197–209.
-
(2014)
Crit Rev Oncol Hematol
, vol.91
, Issue.2
, pp. 197-209
-
-
Zustovich, F.1
Fabiani, F.2
-
8
-
-
84924946874
-
-
From ASCO-prostate cancer: Chemohormonal therapy leads the way in prostate cancer. Nat Rev Clin Oncol. 2014;11(7):380. The E3805 trial was presented at ASCO 2014 and is practice changing. Although the subject of this study is beyond the scope of this review, the change in practice has future implications on the use of many of the CRPC modalities and sequencing
-
From ASCO-prostate cancer: Chemohormonal therapy leads the way in prostate cancer. Nat Rev Clin Oncol. 2014;11(7):380. The E3805 trial was presented at ASCO 2014 and is practice changing. Although the subject of this study is beyond the scope of this review, the change in practice has future implications on the use of many of the CRPC modalities and sequencing.
-
-
-
-
9
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
COI: 1:CAS:528:DC%2BD2cXot1Kmu7s%3D, PID: 1547021
-
Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
-
10
-
-
20544432245
-
Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases
-
PID: 1592830
-
Hartsell WF et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97(11):798–804.
-
(2005)
J Natl Cancer Inst
, vol.97
, Issue.11
, pp. 798-804
-
-
Hartsell, W.F.1
-
11
-
-
0033179896
-
The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch bone metastasis study
-
COI: 1:STN:280:DC%2BD3c%2FktlKntg%3D%3D, PID: 1057769
-
Steenland E et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch bone metastasis study. Radiother Oncol. 1999;52(2):101–9.
-
(1999)
Radiother Oncol
, vol.52
, Issue.2
, pp. 101-109
-
-
Steenland, E.1
-
12
-
-
2442420056
-
Single fraction radiotherapy is efficacious: a further analysis of the Dutch bone metastasis study controlling for the influence of retreatment
-
PID: 1514517
-
van der Linden YM et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch bone metastasis study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys. 2004;59(2):528–37.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.59
, Issue.2
, pp. 528-537
-
-
van der Linden, Y.M.1
-
13
-
-
0033180137
-
-
8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone pain trial working party. Radiother Oncol. 1999;52(2):111-21
-
8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone pain trial working party. Radiother Oncol. 1999;52(2):111-21.
-
-
-
-
14
-
-
79951956249
-
Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline
-
PID: 2127711
-
Lutz S et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965–76.
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.79
, Issue.4
, pp. 965-976
-
-
Lutz, S.1
-
15
-
-
84902584958
-
Radium-223 vs EBRT for multiple painful bone metastases: is less more?
-
Roach 3rd M. Radium-223 vs EBRT for multiple painful bone metastases: is less more? Oncology (Williston Park). 2014;28(4):297–8.
-
(2014)
Oncology (Williston Park)
, vol.28
, Issue.4
, pp. 297-298
-
-
Roach, M.1
-
16
-
-
0035400467
-
Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA)
-
COI: 1:STN:280:DC%2BD3MzislyitQ%3D%3D, PID: 1139524
-
Salazar OM et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys. 2001;50(3):765–75.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.50
, Issue.3
, pp. 765-775
-
-
Salazar, O.M.1
-
17
-
-
78649982628
-
Fractionated wide-field radiation therapy followed by fractionated local-field irradiation for treating widespread painful bone metastasis
-
PID: 2039903
-
Ki Y et al. Fractionated wide-field radiation therapy followed by fractionated local-field irradiation for treating widespread painful bone metastasis. Int J Radiat Oncol Biol Phys. 2011;79(1):220–5.
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.79
, Issue.1
, pp. 220-225
-
-
Ki, Y.1
-
18
-
-
43049152789
-
High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions
-
PID: 1823444
-
Yamada Y et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008;71(2):484–90.
-
(2008)
Int J Radiat Oncol Biol Phys
, vol.71
, Issue.2
, pp. 484-490
-
-
Yamada, Y.1
-
19
-
-
33846246264
-
Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution
-
Gerszten PC et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976). 2007;32(2):193–9.
-
(2007)
Spine (Phila Pa 1976)
, vol.32
, Issue.2
, pp. 193-199
-
-
Gerszten, P.C.1
-
20
-
-
34447276697
-
Is stereotactic radiosurgery the best treatment option for patients with spinal metastases?
-
PID: 1753428
-
Rades D, Schild SE. Is stereotactic radiosurgery the best treatment option for patients with spinal metastases? Nat Clin Pract Oncol. 2007;4(7):400–1.
-
(2007)
Nat Clin Pract Oncol
, vol.4
, Issue.7
, pp. 400-401
-
-
Rades, D.1
Schild, S.E.2
-
21
-
-
35048842987
-
Cyberknife radiosurgery for breast cancer spine metastases: a matched-pair analysis
-
PID: 1778693
-
Gagnon GJ et al. Cyberknife radiosurgery for breast cancer spine metastases: a matched-pair analysis. Cancer. 2007;110(8):1796–802.
-
(2007)
Cancer
, vol.110
, Issue.8
, pp. 1796-1802
-
-
Gagnon, G.J.1
-
22
-
-
67349260007
-
Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases
-
PID: 1909537
-
Sahgal A et al. Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys. 2009;74(3):723–31.
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.74
, Issue.3
, pp. 723-731
-
-
Sahgal, A.1
-
23
-
-
84892419184
-
Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score
-
PID: 2396017
-
Sahgal A et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol. 2013;31(27):3426–31.
-
(2013)
J Clin Oncol
, vol.31
, Issue.27
, pp. 3426-3431
-
-
Sahgal, A.1
-
24
-
-
84879733937
-
Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases
-
PID: 2381629
-
Sahgal A et al. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol. 2013;14(8):e310–20.
-
(2013)
Lancet Oncol
, vol.14
, Issue.8
, pp. 310-320
-
-
Sahgal, A.1
-
25
-
-
77649100060
-
Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases
-
PID: 1973813
-
Rose PS et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol. 2009;27(30):5075–9.
-
(2009)
J Clin Oncol
, vol.27
, Issue.30
, pp. 5075-5079
-
-
Rose, P.S.1
-
26
-
-
84896699065
-
RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results
-
PID: 2489034
-
Ryu S et al. RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results. Pract Radiat Oncol. 2014;4(2):76–81.
-
(2014)
Pract Radiat Oncol
, vol.4
, Issue.2
, pp. 76-81
-
-
Ryu, S.1
-
27
-
-
79960976115
-
Radioisotopes for metastatic bone pain
-
PID: 1458397
-
Roque M et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2003;4, CD003347.
-
(2003)
Cochrane Database Syst Rev
, vol.4
-
-
Roque, M.1
-
28
-
-
84880416044
-
Fighting prostate cancer with radium-223–not your Madame's isotope
-
PID: 2386305
-
Vapiwala N, Glatstein E. Fighting prostate cancer with radium-223–not your Madame's isotope. N Engl J Med. 2013;369(3):276–8.
-
(2013)
N Engl J Med
, vol.369
, Issue.3
, pp. 276-278
-
-
Vapiwala, N.1
Glatstein, E.2
-
29
-
-
66749141846
-
Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of radiology appropriateness criteria expert panel on radiation oncology
-
PID: 1941603
-
Janjan N et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of radiology appropriateness criteria expert panel on radiation oncology. J Palliat Med. 2009;12(5):417–26.
-
(2009)
J Palliat Med
, vol.12
, Issue.5
, pp. 417-426
-
-
Janjan, N.1
-
30
-
-
4544377830
-
Radiopharmaceutical therapy for palliation of bone pain from osseous metastases
-
COI: 1:CAS:528:DC%2BD2cXnsFSmu78%3D, PID: 1529906
-
Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45(8):1358–65.
-
(2004)
J Nucl Med
, vol.45
, Issue.8
, pp. 1358-1365
-
-
Pandit-Taskar, N.1
Batraki, M.2
Divgi, C.R.3
-
31
-
-
0027252452
-
Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
-
COI: 1:STN:280:DyaK3s3jvFGntw%3D%3D, PID: 847823
-
Porter AT et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805–13.
-
(1993)
Int J Radiat Oncol Biol Phys
, vol.25
, Issue.5
, pp. 805-813
-
-
Porter, A.T.1
-
32
-
-
0028233520
-
A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
-
COI: 1:STN:280:DyaK2czhs1yitQ%3D%3D, PID: 751893
-
Quilty PM et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31(1):33–40.
-
(1994)
Radiother Oncol
, vol.31
, Issue.1
, pp. 33-40
-
-
Quilty, P.M.1
-
33
-
-
84863010019
-
Effectiveness of strontium-89 palliative therapy in patients with painful bone metastases
-
COI: 1:CAS:528:DC%2BC3sXit12gtrs%3D, PID: 22593991, discussion 5
-
Zorga P et al. Effectiveness of strontium-89 palliative therapy in patients with painful bone metastases. Ann Acad Med Stetin. 2011;57(1):49–53. discussion 53.
-
(2011)
Ann Acad Med Stetin
, vol.57
, Issue.1
, pp. 49-53
-
-
Zorga, P.1
-
34
-
-
84924946872
-
-
James N, et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both. J Clin Oncol, 2013;31 no. 15_suppl LBA5000
-
James N, et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both. J Clin Oncol, 2013;31 no. 15_suppl LBA5000.
-
-
-
-
35
-
-
0031954325
-
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial
-
COI: 1:CAS:528:DyaK1cXis1Ghtrs%3D, PID: 955206
-
Serafini AN et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574–81.
-
(1998)
J Clin Oncol
, vol.16
, Issue.4
, pp. 1574-1581
-
-
Serafini, A.N.1
-
36
-
-
2342509633
-
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer
-
PID: 1513498
-
Sartor O et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.
-
(2004)
Urology
, vol.63
, Issue.5
, pp. 940-945
-
-
Sartor, O.1
-
37
-
-
33746707858
-
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
-
COI: 1:CAS:528:DC%2BD28XhtFWhsbfK, PID: 1706270
-
Bruland OS et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20 Pt 2):6250s–7s.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6250-6257
-
-
Bruland, O.S.1
-
38
-
-
84924946871
-
Whippany
-
Xofigo® (radium Ra 223 dichloride) injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; May 2013.
-
(2013)
NJ: Bayer HealthCare Pharmaceuticals Inc
-
-
-
39
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
COI: 1:CAS:528:DC%2BC3sXhtFKls77M, PID: 23863050, The ALSYMPCA trial is the first Phase III study to demonstrate and overall survival benefit with the use of a radiopharmaceutical and validated the use of an alpha emitter into the therapeutic armamentarium against CRPC. This is a seminal paper, which is essential for understanding the new landscape of radiopharmaceutical use in this patient population
-
Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. The ALSYMPCA trial is the first Phase III study to demonstrate and overall survival benefit with the use of a radiopharmaceutical and validated the use of an alpha emitter into the therapeutic armamentarium against CRPC. This is a seminal paper, which is essential for understanding the new landscape of radiopharmaceutical use in this patient population.
-
(2013)
N Engl J Med
, vol.369
, Issue.3
, pp. 213-223
-
-
Parker, C.1
-
40
-
-
84901638475
-
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
-
COI: 1:CAS:528:DC%2BC2cXotFyrs74%3D, PID: 24836273, This analysis of the SSEs from ALSYMPCA provide a validation of which SSEs were improved most with Radium-223
-
Sartor O et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738–46. This analysis of the SSEs from ALSYMPCA provide a validation of which SSEs were improved most with Radium-223.
-
(2014)
Lancet Oncol
, vol.15
, Issue.7
, pp. 738-746
-
-
Sartor, O.1
-
41
-
-
84924946870
-
-
Nilsson S, et al. Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating pain relief from the phase 3 ALSYMPCA study. J Clin Oncol. 2014;32:5s, 2014 (suppl; abstr 5069)
-
Nilsson S, et al. Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating pain relief from the phase 3 ALSYMPCA study. J Clin Oncol. 2014;32:5s, 2014 (suppl; abstr 5069).
-
-
-
-
42
-
-
84929392843
-
1.5-Year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study 9
-
Nilsson S, Vogelzang N, Sartor AO, et al. 1.5-Year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study 9. Clin Adv Hematol Oncol. 2014;12(4 Suppl 11):9–10.
-
(2014)
Clin Adv Hematol Oncol
, vol.12
, pp. 9-10
-
-
Nilsson, S.1
Vogelzang, N.2
Sartor, A.O.3
-
43
-
-
84897019369
-
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun
-
PID: 2434422
-
D'Amico AV. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol. 2014;32(4):362–4.
-
(2014)
J Clin Oncol
, vol.32
, Issue.4
, pp. 362-364
-
-
D'Amico, A.V.1
-
44
-
-
84924946869
-
Prostate Cancer
-
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®. Prostate Cancer. Version 4. 2013.
-
(2013)
Version
, pp. 4
-
-
-
45
-
-
84924946868
-
NCT02043678
-
Abiraterone Acetate Compared to Placeb
-
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms; NCT02043678. ClinicalTrials.gov, 2014.
-
(2014)
ClinicalTrials.gov
-
-
Radium-223, D.1
-
46
-
-
2942518111
-
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
-
COI: 1:CAS:528:DC%2BD2cXkvVSrurk%3D, PID: 1517327
-
Saad F et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82.
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.11
, pp. 879-882
-
-
Saad, F.1
-
47
-
-
65649090203
-
Development of a second-generation antiandrogen for treatment of advanced prostate cancer
-
COI: 1:CAS:528:DC%2BD1MXlsVeksro%3D, PID: 1935954
-
Tran C et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–90.
-
(2009)
Science
, vol.324
, Issue.5928
, pp. 787-790
-
-
Tran, C.1
-
48
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
COI: 1:CAS:528:DC%2BC38XhsVKhsLvK, PID: 22894553, The AFFIRM study provided a practice-changing therapeutic modality in the spectrum of CRPC treatment in the post-docetaxel grouping
-
Scher HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. The AFFIRM study provided a practice-changing therapeutic modality in the spectrum of CRPC treatment in the post-docetaxel grouping.
-
(2012)
N Engl J Med
, vol.367
, Issue.13
, pp. 1187-1197
-
-
Scher, H.I.1
-
49
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
PID: 21612468, The COU-AA-301 trial is a seminal publication in the CRPC treatment landscape. It introduced abiraterone as a first line potential treatment modality in the post-docetaxel space
-
de Bono JS et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. The COU-AA-301 trial is a seminal publication in the CRPC treatment landscape. It introduced abiraterone as a first line potential treatment modality in the post-docetaxel space.
-
(2011)
N Engl J Med
, vol.364
, Issue.21
, pp. 1995-2005
-
-
de Bono, J.S.1
-
50
-
-
84866948935
-
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
-
COI: 1:CAS:528:DC%2BC38XhsVCjsbjK, PID: 22995653, The COU-AA-301 trial is a seminal publication in the CRPC treatment landscape. It introduced abiraterone as a first line potential treatment modality in the post-docetaxel space
-
Fizazi K et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92. The COU-AA-301 trial is a seminal publication in the CRPC treatment landscape. It introduced abiraterone as a first line potential treatment modality in the post-docetaxel space.
-
(2012)
Lancet Oncol
, vol.13
, Issue.10
, pp. 983-992
-
-
Fizazi, K.1
-
51
-
-
84870243969
-
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
-
COI: 1:CAS:528:DC%2BC38XhslKkt7fL, PID: 23142059, Significant to this topic, this publication highlighted the ability of abiraterone to decrease skeletal events
-
Logothetis CJ et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210–7. Significant to this topic, this publication highlighted the ability of abiraterone to decrease skeletal events.
-
(2012)
Lancet Oncol
, vol.13
, Issue.12
, pp. 1210-1217
-
-
Logothetis, C.J.1
-
52
-
-
84872078210
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
COI: 1:CAS:528:DC%2BC3sXovVyhtw%3D%3D, PID: 23228172, This paper also is practice changing, introducing abiraterone as a viable treatment option for CRPC in the predocetaxel space, also demonstrated an improvement in skeletal events
-
Ryan CJ et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48. This paper also is practice changing, introducing abiraterone as a viable treatment option for CRPC in the predocetaxel space, also demonstrated an improvement in skeletal events.
-
(2013)
N Engl J Med
, vol.368
, Issue.2
, pp. 138-148
-
-
Ryan, C.J.1
|